{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:10:48Z","timestamp":1793329848660,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00109-018-1699-5","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T04:56:02Z","timestamp":1538974562000},"page":"1251-1266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The combination of everolimus and terameprocol exerts synergistic antiproliferative effects in endometrial cancer: molecular role of insulin-like growth factor binding protein 2"],"prefix":"10.1007","volume":"96","author":[{"given":"Angel","family":"Chao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiao-Yun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-Chin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Shien","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Lung","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chyong-Huey","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,8]]},"reference":[{"key":"1699_CR1","doi-asserted-by":"crossref","unstructured":"Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL et al (2017) Annual report to the nation on the status of cancer, 1975\u20132014, featuring survival. J Natl Cancer Inst 1:109(9)","DOI":"10.1093\/jnci\/djx030"},{"key":"1699_CR2","unstructured":"Cancer Registry Annual Report, 2014 Taiwan: Ministry of Health and Welfare, Executive Yuan 2016 https:\/\/www.hpa.gov.tw\/BHPNet\/English\/Index.aspx"},{"key":"1699_CR3","first-page":"121","volume-title":"Clinical gynecologic oncology","author":"WT Creasman","year":"2012","unstructured":"Creasman WT, Miller DS (2012) Adenocarcinoma of the uterine corpus. In: Di Saia PJ, Creasman WT, Mannel RS, McMeekin DS, Mutch DG (eds) Clinical gynecologic oncology. Elsevier, Philadelphia, pp 121\u2013154"},{"key":"1699_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrclinonc.2010.216","volume":"8","author":"KJ Dedes","year":"2011","unstructured":"Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS (2011) Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 8:261\u2013271","journal-title":"Nat Rev Clin Oncol"},{"key":"1699_CR5","doi-asserted-by":"publisher","first-page":"5932","DOI":"10.1158\/1078-0432.CCR-06-1375","volume":"12","author":"MP Hayes","year":"2006","unstructured":"Hayes MP, Wang H, Espinal-Witter R, Douglas W, Solomon GJ, Baker SJ, Ellenson LH (2006) PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 12:5932\u20135935","journal-title":"Clin Cancer Res"},{"key":"1699_CR6","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1126\/science.1096502","volume":"304","author":"Y Samuels","year":"2004","unstructured":"Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554","journal-title":"Science"},{"key":"1699_CR7","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1073\/pnas.0806514106","volume":"106","author":"HB Salvesen","year":"2009","unstructured":"Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bo TH, Jonassen I, Thomas RK, Zander T, Garraway LA, Oyan AM, Sellers WR, Kalland KH, Meyerson M, Akslen LA, Beroukhim R (2009) Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A 106:4834\u20134839","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1699_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3109\/08977191003745472","volume":"28","author":"M Mireuta","year":"2010","unstructured":"Mireuta M, Darnel A, Pollak M (2010) IGFBP-2 expression in MCF-7 cells is regulated by the PI3K\/AKT\/mTOR pathway through Sp1-induced increase in transcription. Growth Factors 28:243\u2013255","journal-title":"Growth Factors"},{"key":"1699_CR9","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cytogfr.2014.12.001","volume":"26","author":"VC Russo","year":"2015","unstructured":"Russo VC, Azar WJ, Yau SW, Sabin MA, Werther GA (2015) IGFBP-2: the dark horse in metabolism and cancer. Cytokine Growth Factor Rev 26:329\u2013346","journal-title":"Cytokine Growth Factor Rev"},{"key":"1699_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ccr.2005.08.008","volume":"8","author":"N Hay","year":"2005","unstructured":"Hay N (2005) The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8:179\u2013183","journal-title":"Cancer Cell"},{"key":"1699_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1756-8722-2-45","volume":"2","author":"R Yuan","year":"2009","unstructured":"Yuan R, Kay A, Berg WJ, Lebwohl D (2009) Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2:45","journal-title":"J Hematol Oncol"},{"key":"1699_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ygyno.2014.02.017","volume":"133","author":"N Husseinzadeh","year":"2014","unstructured":"Husseinzadeh N, Husseinzadeh HD (2014) mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review. Gynecol Oncol 133:375\u2013381","journal-title":"Gynecol Oncol"},{"key":"1699_CR13","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/bjc.2013.183","volume":"108","author":"I Ray-Coquard","year":"2013","unstructured":"Ray-Coquard I, Favier L, Weber B, Roemer-Becuwe C, Bougnoux P, Fabbro M, Floquet A, Joly F, Plantade A, Paraiso D, Pujade-Lauraine E (2013) Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. Br J Cancer 108:1771\u20131777","journal-title":"Br J Cancer"},{"key":"1699_CR14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10637-014-0198-y","volume":"33","author":"R Tibes","year":"2015","unstructured":"Tibes R, McDonagh KT, Lekakis L, Bogenberger JM, Kim S, Frazer N, Mohrland S, Bassett D, Garcia R, Schroeder K et al (2015) Phase I study of the novel Cdc2\/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias. Investig New Drugs 33:389\u2013396","journal-title":"Investig New Drugs"},{"key":"1699_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1053\/j.seminoncol.2006.04.010","volume":"33","author":"RC Huang","year":"2006","unstructured":"Huang RC, Chang CC, Mold D (2006) Survivin-dependent and -independent pathways and the induction of cancer cell death by tetra-O-methyl nordihydroguaiaretic acid. Semin Oncol 33:479\u2013485","journal-title":"Semin Oncol"},{"key":"1699_CR16","first-page":"204","volume":"11","author":"P Smolewski","year":"2008","unstructured":"Smolewski P (2008) Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs 11:204\u2013214","journal-title":"IDrugs"},{"key":"1699_CR17","doi-asserted-by":"publisher","first-page":"13239","DOI":"10.1073\/pnas.0405407101","volume":"101","author":"CC Chang","year":"2004","unstructured":"Chang CC, Heller JD, Kuo J, Huang RC (2004) Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci U S A 101:13239\u201313244","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1699_CR18","doi-asserted-by":"publisher","first-page":"4601","DOI":"10.1158\/1078-0432.CCR-04-2188","volume":"11","author":"R Park","year":"2005","unstructured":"Park R, Chang CC, Liang YC, Chung Y, Henry RA, Lin E, Mold DE, Huang RC (2005) Systemic treatment with tetra-O-methyl nordihydroguaiaretic acid suppresses the growth of human xenograft tumors. Clin Cancer Res 11:4601\u20134609","journal-title":"Clin Cancer Res"},{"key":"1699_CR19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/neuonc\/nor230","volume":"14","author":"SA Grossman","year":"2012","unstructured":"Grossman SA, Ye X, Peereboom D, Rosenfeld MR, Mikkelsen T, Supko JG, Desideri S, Adult Brain Tumor C (2012) Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro-Oncology 14:511\u2013517","journal-title":"Neuro-Oncology"},{"key":"1699_CR20","doi-asserted-by":"crossref","first-page":"60038","DOI":"10.18632\/oncotarget.11048","volume":"7","author":"CY Lin","year":"2016","unstructured":"Lin CY, Chao A, Wang TH, Lee LY, Yang LY, Tsai CL, Wang HS, Lai CH (2016) Nucleophosmin\/B23 is a negative regulator of estrogen receptor alpha expression via AP2gamma in endometrial cancer cells. Oncotarget 7:60038\u201360052","journal-title":"Oncotarget"},{"key":"1699_CR21","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00109-014-1163-0","volume":"92","author":"CY Lin","year":"2014","unstructured":"Lin CY, Chao A, Wang TH, Hsueh S, Lee YS, Wu TI, Chao AS, Huang HJ, Chou HH, Chang TC, Lai CH (2014) A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer. J Mol Med (Berl) 92:969\u2013981","journal-title":"J Mol Med (Berl)"},{"key":"1699_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1749-0774.2002.tb00105.x","volume":"15","author":"M Nishida","year":"2002","unstructured":"Nishida M (2002) The Ishikawa cells from birth to the present. Hum Cell 15:104\u2013117","journal-title":"Hum Cell"},{"key":"1699_CR23","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1073\/pnas.1222577110","volume":"110","author":"S Zhao","year":"2013","unstructured":"Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD (2013) Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A 110:2916\u20132921","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"233","key":"1699_CR24","first-page":"e237","volume":"78","author":"Y Li","year":"2011","unstructured":"Li Y, Yang X, Su LJ, Flaig TW (2011) Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells. Urology 78(233):e237\u2013e213","journal-title":"Urology"},{"key":"1699_CR25","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/bjc.2012.36","volume":"106","author":"K Hirashima","year":"2012","unstructured":"Hirashima K, Baba Y, Watanabe M, Karashima RI, Sato N, Imamura Y, Nagai Y, Hayashi N, Iyama KI, Baba H (2012) Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma. Br J Cancer 106:876\u2013882","journal-title":"Br J Cancer"},{"key":"1699_CR26","first-page":"5499","volume":"61","author":"JD Heller","year":"2001","unstructured":"Heller JD, Kuo J, Wu TC, Kast WM, Huang RC (2001) Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo. Cancer Res 61:5499\u20135504","journal-title":"Cancer Res"},{"key":"1699_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"S Reagan-Shaw","year":"2008","unstructured":"Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659\u2013661","journal-title":"FASEB J"},{"key":"1699_CR28","volume-title":"Guidance for industry: estimating the maximum safe starting dose in adult healthy volunteer","author":"USFDA","year":"2005","unstructured":"USFDA (2005) Guidance for industry: estimating the maximum safe starting dose in adult healthy volunteer. US Food and Drug Administration, Rockville, MD"},{"key":"1699_CR29","doi-asserted-by":"crossref","first-page":"85529","DOI":"10.18632\/oncotarget.13456","volume":"7","author":"A Chao","year":"2016","unstructured":"Chao A, Chang TC, Lapke N, Jung SM, Chi P, Chen CH, Yang LY, Lin CT, Huang HJ, Chou HH et al (2016) Prevalence and clinical significance of BRCA1\/2 germline and somatic mutations in Taiwanese patients with ovarian cancer. Oncotarget 7:85529\u201385541","journal-title":"Oncotarget"},{"key":"1699_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ (1950) Index for rating diagnostic tests. Cancer 3:32\u201335","journal-title":"Cancer"},{"key":"1699_CR31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jphs.2015.10.008","volume":"129","author":"Y Wei","year":"2015","unstructured":"Wei Y, To KK, Au-Yeung SC (2015) Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells. J Pharmacol Sci 129:210\u2013215","journal-title":"J Pharmacol Sci"},{"key":"1699_CR32","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440\u2013446","journal-title":"Cancer Res"},{"key":"1699_CR33","doi-asserted-by":"crossref","first-page":"24892","DOI":"10.1016\/S0021-9258(19)74549-9","volume":"268","author":"YR Boisclair","year":"1993","unstructured":"Boisclair YR, Brown AL, Casola S, Rechler MM (1993) Three clustered Sp1 sites are required for efficient transcription of the TATA-less promoter of the gene for insulin-like growth factor-binding protein-2 from the rat. J Biol Chem 268:24892\u201324901","journal-title":"J Biol Chem"},{"key":"1699_CR34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.lfs.2008.06.024","volume":"83","author":"SS Solomon","year":"2008","unstructured":"Solomon SS, Majumdar G, Martinez-Hernandez A, Raghow R (2008) A critical role of Sp1 transcription factor in regulating gene expression in response to insulin and other hormones. Life Sci 83:305\u2013312","journal-title":"Life Sci"},{"key":"1699_CR35","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1111\/jcmm.13091","volume":"21","author":"A Li","year":"2017","unstructured":"Li A, Fan S, Xu Y, Meng J, Shen X, Mao J, Zhang L, Zhang X, Moeckel G, Wu D, Wu G, Liang C (2017) Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1\/cyclin axis. J Cell Mol Med 21:1619\u20131635","journal-title":"J Cell Mol Med"},{"key":"1699_CR36","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1158\/1078-0432.CCR-07-0952","volume":"14","author":"SH Oh","year":"2008","unstructured":"Oh SH, Jin Q, Kim ES, Khuri FR, Lee HY (2008) Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt\/mammalian target of rapamycin-mediated increases in survivin expression. Clin Cancer Res 14:1581\u20131589","journal-title":"Clin Cancer Res"},{"key":"1699_CR37","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1038\/s41598-017-03728-3","volume":"7","author":"H Alshaker","year":"2017","unstructured":"Alshaker H, Wang Q, Bohler T, Mills R, Winkler M, Arafat T, Kawano Y, Pchejetski D (2017) Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1. Sci Rep 7:3493","journal-title":"Sci Rep"},{"key":"1699_CR38","doi-asserted-by":"crossref","unstructured":"Thul PJ, Akesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H, Alm T, Asplund A, Bjork L, Breckels LM et al (2017) A subcellular map of the human proteome. Science:356","DOI":"10.1126\/science.aal3321"},{"key":"1699_CR39","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nmeth.2650","volume":"10","author":"J Li","year":"2013","unstructured":"Li J, Lu Y, Akbani R, Ju Z, Roebuck PL, Liu W, Yang JY, Broom BM, Verhaak RG, Kane DW et al (2013) TCPA: a resource for cancer functional proteomics data. Nat Methods 10:1046\u20131047","journal-title":"Nat Methods"},{"key":"1699_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkp168","volume":"37","author":"YS Lee","year":"2009","unstructured":"Lee YS, Chen CH, Tsai CN, Tsai CL, Chao A, Wang TH (2009) Microarray labeling extension values: laboratory signatures for Affymetrix GeneChips. Nucleic Acids Res 37:e61","journal-title":"Nucleic Acids Res"},{"key":"1699_CR41","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.1073\/pnas.0701005104","volume":"104","author":"M Gymnopoulos","year":"2007","unstructured":"Gymnopoulos M, Elsliger MA, Vogt PK (2007) Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A 104:5569\u20135574","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1699_CR42","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1002\/cncr.25515","volume":"116","author":"BM Slomovitz","year":"2010","unstructured":"Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, Walker C, Ramondetta LM, Burke TW, Gershenson DM, Wolf J (2010) A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116:5415\u20135419","journal-title":"Cancer"},{"key":"1699_CR43","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","volume":"33","author":"BM Slomovitz","year":"2015","unstructured":"Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, Levenback C, Zhang Q, Ring K, Munsell MF, Gershenson DM, Lu KH, Coleman RL (2015) Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 33:930\u2013936","journal-title":"J Clin Oncol"},{"key":"1699_CR44","doi-asserted-by":"publisher","first-page":"e0148685","DOI":"10.1371\/journal.pone.0148685","volume":"11","author":"K Kimura","year":"2016","unstructured":"Kimura K, Huang RC (2016) Tetra-O-methyl nordihydroguaiaretic acid broadly suppresses cancer metabolism and synergistically induces strong anticancer activity in combination with etoposide, rapamycin and UCN-01. PLoS One 11:e0148685","journal-title":"PLoS One"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00109-018-1699-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-018-1699-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-018-1699-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T14:57:18Z","timestamp":1662217038000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00109-018-1699-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,8]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["1699"],"URL":"https:\/\/doi.org\/10.1007\/s00109-018-1699-5","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,8]]},"assertion":[{"value":"9 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SJC is an employee of ACT Genomics Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}